论文部分内容阅读
目的:分析两种不同非小细胞肺癌二线药物治疗方案治疗的可行性,为临床医学提供依据。方法:选取我院在2008年6月~2013年8月收治的非小细胞肺癌患者94例,依照治疗方法的平均分为实验组和对照组,对照组患者多西他赛治疗,实验组患者采取吉非替尼治疗,比较分析两组患者的治疗方案的可行性。结果:两组患者的治疗效果差异无统计学意义,P>0.05,实验组患者的不良反应情况症状较轻,明显优于对照组,P<0.05,实验组患者的成本效益比明显大于对照组,P<0.05。结论:在非小细胞肺癌患者的治疗中需要根据患者的实际情况选择合适的治疗方案,提高治疗效果。
Objective: To analyze the feasibility of two different non-small cell lung cancer second-line drug treatment options for clinical medicine to provide the basis. Methods: A total of 94 patients with non-small cell lung cancer who were treated in our hospital from June 2008 to August 2013 were selected and divided into experimental group and control group according to the average of treatment methods. Docetaxel was used in the control group. Patients in the experimental group Gefitinib treatment, comparative analysis of two groups of patients the feasibility of treatment options. Results: There was no significant difference in therapeutic effect between the two groups (P> 0.05). The patients in the experimental group showed less adverse reactions and were significantly better than the control group (P <0.05). The cost-benefit ratio of the experimental group was significantly higher than that of the control group , P <0.05. Conclusion: In the treatment of patients with non-small cell lung cancer need to select the appropriate treatment according to the actual situation of patients, improve the treatment effect.